---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070910"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:37:25.959647+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q1 2025 net loss $5.9M; cash $24.6M; KOURAGE trial data due end of 2025

## Summary
- Net loss of $5.9M in Q1 2025 vs. net income of $0.1M in Q1 2024; R&D expenses rose to $4.2M.
- Cash, cash equivalents and short-term investments of $24.6M; runway expected into mid-2026.
- Phase 2 KOURAGE trial (AKI + respiratory failure) enrollment ongoing; data expected around end of 2025.
- Post-hoc analysis from CARDEA showed 62.7% relative mortality reduction for Auxora vs. placebo in AKI subset.
- End-of-Phase 2 meeting with FDA for AP/SIRS planned mid-2025; credit facility with Avenue Capital ($32.5M total).

## SEC filing metadata
- accession: 0000950170-25-070910
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/0000950170-25-070910-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017025070910/ck0001534133-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070910
- JSON: https://secwatch.observer/filing/0000950170-25-070910.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070910.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.